Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Humira

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Objective To demonstrate clinical equivalence of adalimumab biosimilar candidate BI 695501 with Humira. Methods Patients with… Expand
Is this relevant?
2017
2017
ABSTRACT Biosimilars are biological products that are highly similar to existing products approved by health authorities… Expand
Is this relevant?
2017
2017
AIMS To compare the pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a biosimilar of adalimumab, with… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
BackgroundThis study aimed to compare efficacy and safety of test-adalimumab (CinnoRA®, CinnaGen, Iran) to the innovator product… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2016
2016
Abstract Aim In this study, efficacy, tolerability and safety of biosimilar adalimumab (Exemptia; Zydus Cadila) was compared with… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2016
2016
Aims The aim of the study was to compare the pharmacokinetics (PK), safety and tolerability of the proposed adalimumab biosimilar… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2016
Review
2016
  • Peter Norman
  • Pharmaceutical patent analyst
  • 2016
  • Corpus ID: 29403624
The world's top selling drug, adalimumab (AbbVie's Humira), generated sales in excess of US$13 billion in 2015. The primary… Expand
Is this relevant?
2012
2012
BACKGROUND Human embryos develop at varying rates in culture, with only a fraction of the eggs retrieved developing to 'transfer… Expand
Is this relevant?
2011
2011
PROBLEM This study compares the birth defect rate in women using preconception TNF-α inhibitor (Adalimumab) during an in vitro… Expand
Is this relevant?
2004
2004
FDA-Approved Indications  Moderately to severely active rheumatoid arthritis (RA)  Moderately to severely active polyarticular… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?